CD274 and neoplasm: However, the effective response rate for immunotherapy is limited to fraction of gastric cancer patients, and the commonly used markers, such as PD-L1, tumor mutation burden and tumor infiltrating leukocytes, also have certain defects in assessing the response to immunotherapy [12].